Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 11/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | STK3 | Q13188 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.35 |
| ▸ | SLC2A3 | P11169 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217920 | 0.86 | ROCK2 (0.43) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL21217625 | 0.85 | ROCK2 (0.54) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL22967199 | 0.80 | ROCK2 (0.38) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL21218012 | 0.79 | ROCK2 (0.40) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL21217638 | 0.79 | ROCK2 (0.42) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL22966708 | 0.79 | ROCK2 (0.39) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL22966762 | 0.78 | ROCK2 (0.40) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL21217512 | 0.76 | ROCK2 (0.41) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL21217922 | 0.76 | SMN1; SMN2 (0.43) | ROCK1ROCK2DYRK1ACLK2BLK | |
| SCHEMBL21217642 | 0.76 | ROCK2 (0.42) | ROCK1ROCK2DYRK1ACLK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | ROCK1 2/4885ROCK2 1/4885DYRK1A 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.